Skip to Content
Merck
  • Controlled release of lidocaine hydrochloride from the surfactant-doped hybrid xerogels.

Controlled release of lidocaine hydrochloride from the surfactant-doped hybrid xerogels.

Journal of controlled release : official journal of the Controlled Release Society (2005-05-25)
Zhijian Wu, Hyeonwoo Joo, Tai Gyu Lee, Kangtaek Lee
ABSTRACT

We investigate the controlled release of lidocaine hydrochloride from the doped silica-based xerogels. In the xerogel preparation, tetraethoxysilane (TEOS), methyltriethoxysilane (MTES), and propyltriethoxysilane (PTES) are used as precursors, and a nonionic surfactant Igepal CO 720 is used as a dopant. The experimental results suggest that the release of lidocaine hydrochloride can be easily controlled by partially substituting TEOS with the organosilanes, and/or by adding the dopant. Adding the organosilane precursors lowers the release of both the drug and the surfactant in the order of TEOS, MTES/TEOS, and PTES/TEOS xerogels. The release from the PTES/TEOS xerogels is much lower than that from the other xerogels. The release of lidocaine hydrochloride is obviously suppressed by the addition of Igepal CO 720, while the release of Igepal CO 720 is slightly promoted by the addition of the drug. The overall release process is found to be diffusion-controlled, and the release behaviors can be well explained by considering the effects of the textual properties of the xerogels and the interactions among the drug, the surfactant, and the xerogel matrices.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
IGEPAL® CA-720, average Mn ~735